$1.66
5.73% yesterday
Nasdaq, Nov 25, 10:17 pm CET
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

BioAtla Inc Stock price

$1.66
-0.33 16.58% 1M
-0.05 2.92% 6M
-0.80 32.52% YTD
+0.19 12.93% 1Y
-24.04 93.54% 3Y
-16.34 90.78% 5Y
-16.34 90.78% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.09 5.73%
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

Key metrics

Market capitalization $80.25m
Enterprise Value $24.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.27
P/S ratio (TTM) P/S ratio 7.30
P/B ratio (TTM) P/B ratio 3.49
Revenue (TTM) Revenue $11.00m
EBIT (operating result TTM) EBIT $-86.24m
Free Cash Flow (TTM) Free Cash Flow $-85.08m
Cash position $56.52m
EPS (TTM) EPS $-1.70
P/E forward negative
P/S forward 7.30
EV/Sales forward 2.27
Short interest 11.26%
Show more

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a BioAtla Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a BioAtla Inc forecast:

Buy
75%
Hold
25%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
11 11
-
100%
- Direct Costs 1.07 1.07
7% 7%
10%
9.94 9.94
964% 964%
90%
- Selling and Administrative Expenses 21 21
14% 14%
191%
- Research and Development Expense 74 74
28% 28%
674%
-85 -85
34% 34%
-774%
- Depreciation and Amortization 1.07 1.07
7% 7%
10%
EBIT (Operating Income) EBIT -86 -86
34% 34%
-784%
Net Profit -82 -82
34% 34%
-744%

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
Finbold
11 days ago
After the famous ‘Big Short' investor Michael Burry abandoned his 2023 bet against the semiconductor industry – though, interestingly, the short position may not have been wrong, only poorly timed – he again stirred controversy with his persistent bullishness about Chinese stocks.
Neutral
Seeking Alpha
17 days ago
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. ...
Neutral
Seeking Alpha
about 2 months ago
BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Ozuriftamab Vedotin shows promising Phase 2 results and received FDA Fast Track Designation, e...
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 65
Founded 2007
Website www.BioAtla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today